AIM Center Director, Department Chair and Distinguished Professor, Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Research Interests: membrane atg8ylation; autophagy; immunology; cell biology.

Head of Department Human Medicine, MSB Medical School Berlin, Rüdesheimer Str 50, 14197 Berlin, Germany.
Research Interests: autophagy; Autophagy-Targeting Chimera (AUTAC); ATG4; deubiquitinases; drug discovery.

Distinguished Professor and Chair, Department of Pathology, University of California, San Francisco, CA, USA.
Research Interests: autophagy; extracellular vesicles; membrane AT8ylation; secretory autophagy; cancer; metastasis.

Research Interests: cancer signalling pathways.

Bradley Distinguished Professor, Centre for Cancer Biology, Adelaide University, Australia.
Research Interests: cell death; ubiquitination; ubiquitin ligases; extracellular vesicles.

Department of Biomedicine, Aarhus University, Denmark.
Research Interests: mechanism of autophagy; aggrephagy; autophagy-infection interaction; unconventional functions iof the ATG proteins.

Research Interests: My group studies the molecular mechanisms of autophagy and CASM, with a particular focus on how ATG8-specific E3-like complexes are targeted to damaged or remodeling intracellular membrane compartments. A second major theme is defining the downstream consequences of CASM and how these outputs influence endolysosomal homeostasis. To address these questions, we develop complementary in cellulo and in vitro approaches to dissect these pathways at molecular resolution.

Plant Science Research Laboratory - National Center for Scientific Research, Toulouse, France.
Research Interests: deconstructing K63 polyubiquitination in plants; plasma membrane protein degradation; endocytosis; targeted protein degradation.

School of Health Sciences, Faculty of Medicine, University of Iceland, Iceland.
Research Interests: membrane Atg8ylation; autophagy; lipid metabolism; cancer cell biology.

Member and Dean, Cell Biology Program, Gerstner Sloan Kettering Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY, USA .
Research Interests: cell death; autophagy; lysosomes; Atg8ylation; CASM.

Centre for Cell Biology and Chronic Disease, Institute for Molecular Bioscience, the University of Queensland, St. Lucia, Australia.
Research Interests: biological sciences; genetics; immunology.

Institute of Biomedicine, University of Turku, Finland.
Research Interests: cell biology; autophagy; small GTPases, RAB24.

Research Interests: autophagy (selective & secretory); pancreatic & digestive diseases.

Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Research Interests: metabolism; autophagy; intracellular trafficking; neurodegeneration; cancer.

Department of Biology, Faculty of Science, Eberhard Karls University Tübingen, Germany.
Research Interests: mechanism of autophagy; autophagy signalling pathways; WIPI beta-propeller proteins in health and disease.

Department of Medicine, Health and Medical University, Potsdam, Germany.
Research Interests: ubiquitin proteasome system; primary cilia; proteostasis; ageing; GID/CTLH complex.

Department of Biomedicine, Aarhus University, Denmark.
Research Interests: My research focuses on understanding the role of human autophagy modifiers (ATG8 family proteins) and other proteins in regulating selective autophagy at the molecular level. Specifically, I am interested in studying the interactions of ATG8s with proteins, their fragments, and chemical compounds. I have strong expertise in protein:protein and protein:ligand interactions, which I assess using biophysical, biochemical and structural methods. I am investigating the basic principles of how autophagic cargo can be selectively sequestered for degradation by autophagy. I am constantly searching for and studying novel protein motifs that could interact with ATG8s via LDS or UDS sites. My research aims to develop small molecules for autophagy-related targeted protein degradation, which could be used to effectively treat human diseases.
